Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest (IMICA): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial
Open Access
- 20 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 21 (1), 1-12
- https://doi.org/10.1186/s13063-020-04783-4
Abstract
Background: Resuscitated out-of-hospital cardiac arrest (OHCA) patients who remain comatose at admission are at high risk of morbidity and mortality. This has been attributed to the post-cardiac arrest syndrome (PCAS) which encompasses multiple interacting components, including systemic inflammation. Elevated levels of circulating interleukin-6 (IL-6), a pro-inflammatory cytokine, is associated with worse outcomes in OHCA patients, including higher vasopressor requirements and higher mortality rates. In this study, we aim to reduce systemic inflammation after OHCA by administering a single infusion of tocilizumab, an IL-6 receptor antibody approved for use for other indications. Methods: Investigator-initiated, double-blinded, placebo-controlled, single-center, randomized clinical trial in comatose OHCA patients admitted to an intensive cardiac care unit. Brief inclusion criteria: OHCA of presumed cardiac cause, persistent unconsciousness, age >= 18 years. Intervention: 80 patients will be randomized in a 1:1 ratio to a single 1-h intravenous infusion of either tocilizumab or placebo (NaCl). During the study period, patients will receive standard of care, including sedation and targeted temperature management of 36 degrees for at least 24 h, vasopressors and/or inotropes as/if needed, prophylactic antibiotics, and any additional treatment at the discretion of the treating physician. Blood samples are drawn for measurements of biomarkers included in the primary and secondary endpoints during the initial 72 h. Primary endpoint: reduction in C-reactive protein (CRP). Secondary endpoints (abbreviated): cytokine levels, markers of brain, cardiac, kidney and liver damage, hemodynamic and hemostatic function, adverse events, and follow-up assessment of cerebral function and mortality. Discussion: We hypothesize that reducing the effect of circulating IL-6 by administering an IL-6 receptor antibody will mitigate the systemic inflammatory response and thereby modify the severity of PCAS, in turn leading to lessened vasopressor use, more normal hemodynamics, and better organ function. This will be assessed by primarily focusing on hemodynamics and biomarkers of organ damage during the initial 72 h. In addition, pro-inflammatory and anti-inflammatory cytokines will be measured to assess if cytokine patterns are modulated by IL-6 receptor blockage.Funding Information
- Hjertecenterets Forskningsudvalg (N/A)
- Hjerteforeningen (19-R135-A9302-22125)
- Region Hovedstaden (A6030)
- Novo Nordisk Fonden (NNF17OC0028706)
This publication has 36 references indexed in Scilit:
- Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary SyndromesRevista Española de Cardiología (English Edition), 2013
- Interleucina 6 y proteína C reactiva ultrasensible para la predicción de la evolución clínica en síndromes coronarios agudos sin elevación del segmento STRevista Espanola de Cardiologia, 2013
- Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL StudyJournal of the American Heart Association, 2013
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAnnals Of The Rheumatic Diseases, 2012
- Assessment of Procalcitonin to Predict Outcome in Hypothermia-Treated Patients after Cardiac ArrestCritical Care Research and Practice, 2011
- Outcome, timing and adverse events in therapeutic hypothermia after out‐of‐hospital cardiac arrestActa Anaesthesiologica Scandinavica, 2009
- Post–Cardiac Arrest SyndromeCirculation, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Postresuscitation disease after cardiac arrest: a sepsis-like syndrome?Current Opinion in Critical Care, 2004
- Penetration of interleukin-6 across the murine blood-brain barrierNeuroscience Letters, 1994